Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EBITDA: 2019-2024

Historic EBITDA for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$376.7 million.

  • Beam Therapeutics' EBITDA fell 19.35% to -$111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.6 million, marking a year-over-year decrease of 197.27%. This contributed to the annual value of -$376.7 million for FY2024, which is 190.88% down from last year.
  • Latest data reveals that Beam Therapeutics reported EBITDA of -$376.7 million as of FY2024, which was down 190.88% from -$129.5 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' EBITDA ranged from a high of -$129.5 million in FY2023 and a low of -$376.7 million during FY2024.
  • In the last 3 years, Beam Therapeutics' EBITDA had a median value of -$291.5 million in 2022 and averaged -$265.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 55.57% in 2023, then plummeted by 190.88% in 2024.
  • Over the past 5 years, Beam Therapeutics' EBITDA (Yearly) stood at -$194.6 million in 2020, then crashed by 90.47% to -$370.7 million in 2021, then grew by 21.37% to -$291.5 million in 2022, then soared by 55.57% to -$129.5 million in 2023, then tumbled by 190.88% to -$376.7 million in 2024.